Posts tagged ‘abiraterone acetate price’
March 3rd, 2012
At the recent European Association of Urology (EAU) Annual Congress in Paris, one of the rumours was that the price of abiraterone (Zytiga) has been discounted 40% to the UK National Health Service (NHS) in order to obtain reimbursement approval from the National Institute for Health & Clinical Excellence (NICE).
As Sally notes in her video report from EAU 2012, if true, this has important commercial implications in the advanced prostate cancer market and potential new entrants such as MDV3100.
When looking at the prostate cancer competitive landscape and a market entry strategy, one of the issues to consider is reimbursement.
Regulatory approval to market a drug in Europe does not automatically mean it will be reimbursed or paid for by healthcare providers. Abiraterone is a good example of this.
Another driver of price and reimbursement will be the cumulative cost of treatment for advanced prostate cancer. This is set to increase dramatically as new products such as MDV3100 and Alpharadin come to market, and their use moves from post-chemotherapy to the pre-chemotherapy setting.
You can gain more insights on some of the future challenges by watching Sally’s excellent conference coverage video from EAU 2012:
There is also more information from EAU 2012 on Biotech Strategy Blog e.g. on Bayer’s Expanded Access Program for Alpharadin and an update on Millennium’s orteronel (TAK-700), a competitor to abiraterone.
Sally’s next conference video will be from the forthcoming American Assocation for Cancer Research (AACR) 2012 annual meeting that takes in place Chicago from March 31 – April 4. We hope to see you there.
April 29th, 2011
Sally Church on Pharma Strategy Blog has written about the FDA approval yesterday of Ortho Biotech’s ($JNJ) abiraterone acetate, brand name Zytiga for the treatment of castration resistant prostate cancer in patients who have received prior chemotherapy with docetaxel.
The final data showed a 4.6 month increase in overall survival (OS) in these very sick patients in late stage disease. It is to be expected that the response will be significantly better in patients treated earlier.
As Sally states in her post, “it is good to see new treatment options emerge for the treatment of castrate resistant prostate cancer.”
Abiraterone treatment has been priced competitively by JNJ, with a treatment price of around $40K ($5,000 per month for a median treatment cycle of 8 months). As Sally notes “this is very fair.”
The commercial impact for sanofi-aventis is likely to be huge. It’s hard not to see elderly or frail patients preferring 4 pills a day compared to chemotherapy with a side-effect profile that is far from optimal. The price of abiraterone acetate (Zytiga) is lower than cabazitaxel (Jevtana), which was approved early last year. The market opportunity for Jevtana looks less promising now that it has competition.
Sally, in her insightful post on Pharma Strategy Blog, also notes a possible impact on sipuleucel-T (Provenge) from Dendreon, which is $93K for three infusions. It’s hard not to see some off-label usage from urologists given that phase III trials for use of abiraterone in the pre-chemotherapy setting are already enrolled.
The prostate cancer market is currently a very dynamic and competitive one. With more new drugs on the horizon that may potentially be improvements on abiraterone acetate e.g. MDV3100 and ARN-509, it’s an exciting market to watch.
Sally Church has a number of posts on Pharma Strategy Blog that discuss the science and pharma marketing strategy for prostate cancer new products.